Network interactions in schizophrenia - Therapeutic implications

Brain Research Reviews

Volumn 31, Issue 2-3, 2000, Pages 342-349

  Carlsson, Arvid ^a   Waters, Nicholas ^a   Waters, Susanna ^a   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antipsychotics; Dopamine; Glutamate; Neurocircuits; Neurotransmitters; Schizophrenia

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DEXAMPHETAMINE; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KETAMINE; LYSERGIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PHENCYCLIDINE; SEROTONIN RECEPTOR;

ANIMAL MODEL; BRAIN DYSFUNCTION; CONFERENCE PAPER; DOPAMINE RELEASE; HUMAN; HYPOTHESIS; NERVE CELL NETWORK; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; THALAMUS;

ANIMALS; BRAIN; HUMANS; NERVE NET; SCHIZOPHRENIA;

EID: 0034010373     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(99)00050-8     Document Type: Conference Paper

References (32)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Laruelle M.et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry. 155:1998;761-767.
2. Ågren H., Reibring L., Hartvig P., Tedroff J., Bjurling P., Hornfeldt K.et al. Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatr. Scand. 83:1991;449-455.
3. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
4. Breier A., Su T-P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A.et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA. 94:1997;2569-2574.
5. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
6. A. Carlsson The dopamine theory revisited, in: S.R. Hirsch, D.R. Weinberger (Eds), Schizophrenia, Blackwell Science, Oxford, 1995, pp 379-400.
7. Carlsson M.L. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J. Neural Transm. 100:1995;225-237.
8. Carlsson M.L., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226.
9. Carlsson M.L., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
10. Carlsson M.L., Svensson A. Interfering with glutamatergic neurotransmission by means of MK-801 administration discloses the locomotor stimulatory potential of other transmitter systems in rats and mice. Pharmacol. Biochem. Behav. 36:1990;45-50.
11. Carlsson M.L. Hypothesis - Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? J. Neural Transm. [GenSect]. 94:1993;1-10.
12. M.L. Carlsson, P. Martin, M. Nilsson, S.M. Sorensen, A. Carlsson, S. Waters, N. Waters, The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist than dopamine agonist-induced hyperactivity in mice, J. Neural Transm. (1999) in press.
13. Dao-Costellana M-H., Paillère-Martinot M-L., Hantraye P., Attar-Lévy D., Rémy P., Crouzel C.et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr. Res. 23:1997;167-174.
14. B. Garland Bunney, W.E. Bunney, A. Carlsson, Schizophrenia and glutamate, in: F.E. Bloom, D.J. Kupfer (Eds), Psychopharmacology: the Fourth Generation of Progress, Raven Press, New York, 1995, pp 1203-1214.
15. Gellman R.L., Aghajanian G.K. IPSPs in pyramidal cells in piriform cortexevoked by monoamine excitation of interneurons demonstrate a convergence of inputs. Soc. Neurosci. Abstr. 17(1):1991;989.
16. Hansson L.O., Waters N., Winblad B., Gottfries C-G., Carlsson A. Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J. Neural Transm. 98:1994;217-235.
17. 2 autoreceptor ligands. Modeling of dopamine synthesis and release in vivo by means of partial least squares regression. J. Med. Chem. 38:1995;3121-3131.
18. Hietala J., Syvälahti E., Vuorio K., Någren K., Lehikoinen P., Ruotsalalainen U.et al. Striatal D2-dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry. 51:1994;116-123.
19. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmüller Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
20. Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol. Psychiat. 43:1998;2-11.
21. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E.et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA. 20(93(17)):1996;9235-9240.
22. 11-labelled l-dopa and positron emission tomography (PET), Abstract, 36th Annual ACNP Meeting, December 8-12 (1997) 290.
23. Lodge D. Modulation of N-methylaspartate receptor channel complexes. Drugs of Today. 25:1989;395-411.
24. Martin P., Waters N., Schmidt C.J., Carlsson A., Carlsson M.L. Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. J. Neural Transm. 105:1998;365-396.
25. P. Martin, M.L. Carlsson, S. Hjorth, Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats, NeuroReport (1999) in press.
26. Miller D.W., Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull. 40:1996;57-62.
27. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
28. 2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
29. Sonesson C., Lin C-H., Hansson L., Waters N., Svensson K., Carlsson A.et al. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships. J. Med. Chem. 37:1994;2735-2753.
30. Svensson K., Hjorth S., Clark D., Carlsson A., Wikström H., Andersson B.et al. (+)-UH 232 and (+)-UH 242: Novel stereoselective DA receptor antagonists with preferential action on autoreceptors. J. Neural Transm. 65:1986;1-27.
31. Tamminga C.A., Crayton J.C., Chase T.N. Muscimol: GABA agonist therapy in schizophrenia. Am. J. Psychiatry. 135:1978;746-748.
32. Waters N., Lundgren C., Hansson L.O., Carlsson M.L. Concurrent locomotor stimulation and decrease in dopamine in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755. J. Neural Transm. 103:1996;117-129.